Mesenchymal stem cell therapy in diabetes mellitus: progress and challenges

Area of Science:

• Regenerative Medicine
• Endocrinology
• Cell Therapy

Background:

• Advanced type 2 diabetes mellitus presents significant health risks due to complications affecting the cardiovascular, nervous, and renal systems.
• Islet transplantation, while providing insulin-secreting cells, faces limitations including donor scarcity, graft rejection, and the need for immunosuppression.
• Stem cell therapy emerges as a potential solution for type 2 diabetic patients with hyperglycemia unresponsive to insulin therapy.

Purpose of the Study:

• To review the advantages of mesenchymal stem cells (MSCs) over other stem cell types for treating type 2 diabetes.
• To explore the mechanisms by which MSC transplantation may restore normoglycemia in type 2 diabetic patients.
• To discuss the sources of MSCs, including autologous cells from diabetic patients, and differentiation protocols for optimal transplant outcomes.

Main Methods:

• Review of existing literature on stem cell therapy for type 2 diabetes.
• Focus on mesenchymal stem cells (MSCs) and their therapeutic potential.
• Analysis of mechanisms underlying MSC-mediated normoglycemia restoration.

Main Results:

• Mesenchymal stem cells (MSCs) show promise as an alternative to islet transplantation for type 2 diabetes.
• Autologous MSC transplantation is highlighted for its potential to avoid prolonged hospital stays and immunosuppressive therapy.
• The review examines MSCs' advantages and mechanisms for restoring normoglycemia.

Conclusions:

• Mesenchymal stem cells (MSCs) represent a viable therapeutic strategy for type 2 diabetes, particularly when using autologous sources.
• Further research into MSC differentiation protocols and transplantation mechanisms is crucial for optimizing treatment outcomes.
• MSC therapy offers a potentially more sustainable and less invasive approach compared to traditional islet transplantation.